Page 3 - Nyse Path News Today

DnB Asset Management AS reduced its position in UiPath Inc. (NYSE:PATH – Free Report) by 9.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 105,998 shares of the healthcare company’s stock after selling 11,311 shares during the period. DnB Asset Management AS’s holdings in UiPath were worth […]

UiPath Inc. (NYSE:PATH – Get Free Report) dropped 4.2% during mid-day trading on Wednesday following insider selling activity. The stock traded as low as $25.10 and last traded at $25.15. Approximately 1,923,240 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 8,097,256 shares. The stock had previously closed […]

UiPath Inc. (NYSE:PATH – Get Free Report) CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $24.88, for a total value of $995,200.00. Following the sale, the chief financial officer now owns 1,103,754 shares in the company, […]

UiPath Inc. (NYSE:PATH – Get Free Report) Director Rich Wong sold 100,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $22.94, for a total value of $2,294,000.00. Following the completion of the sale, the director now directly owns 667,730 shares of the […]

UiPath (NYSE:PATH – Free Report) had its target price upped by Royal Bank of Canada from $19.00 to $24.00 in a report published on Friday morning, Benzinga reports. They currently have a sector perform rating on the healthcare company’s stock. PATH has been the subject of a number of other research reports. Mizuho upped their […]

UiPath (NYSE:PATH – Free Report) had its target price increased by Mizuho from $18.00 to $22.00 in a research report report published on Friday, Benzinga reports. The firm currently has a neutral rating on the healthcare company’s stock. A number of other analysts also recently commented on the company. Needham & Company LLC reiterated a […]

UiPath (NYSE:PATH – Free Report) had its price target boosted by Needham & Company LLC from $20.00 to $25.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has a buy rating on the healthcare company’s stock. Several other equities analysts have also recently weighed in on PATH. Mizuho raised their price […]

UiPath (NYSE:PATH – Free Report) had its target price raised by BMO Capital Markets from $19.00 to $24.00 in a report published on Friday, Benzinga reports. The firm currently has a market perform rating on the healthcare company’s stock. A number of other brokerages have also issued reports on PATH. Canaccord Genuity Group lifted their […]

UiPath Inc. (NYSE:PATH – Get Free Report)’s share price gapped up prior to trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $19.00 to $22.00. The stock had previously closed at $19.76, but opened at $22.61. JPMorgan Chase & Co. currently has a neutral rating on the stock. […]

River & Mercantile Asset Management LLP purchased a new position in UiPath Inc. (NYSE:PATH – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 32,990 shares of the healthcare company’s stock, valued at approximately $546,000. Other large investors have also recently modified their […]